Travere Therapeutics Inc.

4 trials 1 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

2 Completed trials

15 Countries active

4 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 3 Phase II: 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

IgA nephropathy 2 Focal segmental glomerulosclerosis 2 Alport's syndrome 1 Homocystinuria 1

Top IMPs

SPARSENTAN 3 PEGTIBATINASE 1

All trials

4 total

A study to investigate efficacy and safety with pegtibatinase compared to placebo in participants ≥12 to ≤65 years of age with classical hom… Pending

2023-504135-40-00 Phase III 8 countries PEGTIBATINASE
Safety, efficacy and pharmacokinetics of sparsentan in pediatric subjects with selected kidney diseases. Recruiting

2023-505497-14-00 Phase II 6 countries SPARSENTAN
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Phase III 11 countries SPARSENTAN
Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended

2023-505494-32-00 Phase III 12 countries SPARSENTAN

Showing 1–4 of 4 trials

← All sponsors A–Z